GeneDx Holdings (WGS) Enterprise Value (2020 - 2026)

GeneDx Holdings (WGS) has reported Enterprise Value for 7 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value fell 23.93% year-over-year to $1.9 billion in Q2 2026; TTM through Jun 2026 was $1.9 billion, a 23.93% decrease from a year earlier, with the FY2025 full-year figure at $3.6 billion, up 80.52% from the prior year.
• Enterprise Value was $1.9 billion for Q2 2026 at GeneDx Holdings, up from $1.7 billion in the prior quarter.
• Over five years, Enterprise Value peaked at $24.5 billion in Q1 2022 and troughed at -$58.7 million in Q4 2023.
• A 5-year average of $2.7 billion and a median of $1.7 billion in 2022 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value sank 112.92% in 2023 and soared 18970.99% in 2024, its largest moves.
• Over 5 years, Enterprise Value stood at $454.5 million in 2022, then sank by 112.92% to -$58.7 million in 2023, then surged by 3527.52% to $2.0 billion in 2024, then surged by 80.52% to $3.6 billion in 2025, then slumped by 47.32% to $1.9 billion in 2026.
• The last three Enterprise Value figures came in at $1.9 billion (Q2 2026), $1.7 billion (Q1 2026), and $3.6 billion (Q4 2025), per Business Quant data.